2018 Corporate Social Responsibility Report

Company: FOSUN PHARMA (2196)
Year: 2018
Published: 2019-04-17
Status: Processed
View Report

Extracted ESG KPIs

KPIs are organized by ESG aspects.

The types of emissions and respective emissions data.

Indicator Unit 2016 2017 2018 Report Pages
Annual discharge of COD ton 846.5 44
Annual discharge of COD - Healthcare services ton 45.6 44
Annual discharge of COD - Medical devices and medical diagnosis ton 14.9 44
Annual discharge of COD - Pharmaceutical manufacturing and research and development ton 786 44
Annual emission of VOCs by the Group tons 18.11 45
Annual total discharge of NH3-N ton 253.7 44
Annual total discharge of NH3-N - Healthcare services ton 6.5 44
Annual total discharge of NH3-N - Medical devices and medical diagnosis ton 0.8 44
Annual total discharge of NH3-N - Pharmaceutical manufacturing and research and development ton 246.4 44
COD tons/year 490 841 847 43
Change in total NOx discharge over 2017 % -47.8 44
Emission of COD tons/year 490 841 847 87
Emission of NH3-N tons/year 60.55 486 254 87
Emission of nitrogen oxides tons/year 466 239 251 87
Emission of particles tons/year 19 41 44 87
Emission of sulphur oxides tons/year 485 245 279 87
Increase in nitrogen oxides emission from Shine Star tons 22.73 45
Increase in particulates emission from Shine Star tons 3.56 45
Increase in sulfur dioxide emission from Shine Star tons 39.16 45
Investment in VOCs emission reduction projects million RMB 7.87 45
NH₃-N tons/year 60.55 486 254 43
NOₓ tons/year 466 239 251 43
Non-methane hydrocarbon tons/year 18 43
Number of key indicators disclosed (including investment income, ongoing project, total number of employees, social contribution value per share, total wastewater, nitrogen oxide emissions) count 59 99
Particles tons/year 19 41 44 43
SO₂ tons/year 485 245 279 43
Total emission of nitrogen oxides tons 119.03 45
Total emission of particulates tons 29.71 45
Total emission of sulfur dioxide tons 33.53 45

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 Report Pages
Carbon emission arising from fossil fuel source ton 288447 338285 397106 50
Carbon emission arising from purchased electricity/steam source ton 457732 484501 389265 50
Carbon reduction by Carelife Pharma ton 15 51
Carbon reduction by Chemo Biopharm ton 65 51
Carbon reduction by Dongting Pharma ton 74 51
Carbon reduction by Erye Pharma ton 35 51
Carbon reduction by Gland Pharma ton 20 51
Carbon reduction by Guangji Hospital ton 262 51
Carbon reduction by Guilin Pharma ton 2666 51
Carbon reduction by Hongqi Pharma ton 1018 51
Carbon reduction by Huaiyin Medical ton 35 51
Carbon reduction by Jiangsu Changxing ton 352 51
Carbon reduction by Jimin Cancer Hospital ton 54 51
Carbon reduction by Shanghai Transfusion ton 8.5 51
Carbon reduction by Wanbang Folon ton 77 51
Carbon reduction by Yaneng Bio ton 172 51
Carbon reduction by Yao Pharma ton 1082 51
Carbon reduction by Zhaohui Pharma ton 56 51
Total carbon emission ton/year 746179 822786 786371 87
Total carbon emissions of Fosun Pharma Group ton 746179 822786 786371 50

Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 Report Pages
Decrease in total amount of solid waste compared to 2017 tons -3171 46
Hazardous Waste Intensity (Unit: kg/RMB10000 of output value) kg/RMB10000 of output value 1.29 1.07 43
Hazardous waste subject to landfill disposal tons 28.7 46
Hazardous waste treated in other ways (including storage for later treatment) tons 115.9 46
Solid wastes emission by segment - Healthcare services - Hazardous waste tons 648.6 46
Solid wastes emission by segment - Medical devices and medical diagnosis - Hazardous waste tons 16 46
Solid wastes emission by segment - Pharmaceutical manufacturing and research and development - Hazardous waste tons 2018.6 46
Solid wastes emission by segment - Total - Hazardous waste tons 2683.2 46
Total amount of hazardous waste tons 2683.2 46
Total wastewater tons/year 6785400 7315890 7565178 43, 87
Total wastewater discharge ton 7565178 44
Total wastewater discharge - Healthcare services ton 941958 44
Total wastewater discharge - Medical devices and medical diagnosis ton 157004 44
Total wastewater discharge - Pharmaceutical manufacturing and research and development ton 6466216 44

Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 Report Pages
Percentage decrease in total amount of solid waste compared to 2017 % -3.6 46
Solid wastes emission by segment - Healthcare services - Domestic waste tons 3061.5 46
Solid wastes emission by segment - Healthcare services - Industrial solid waste (non-hazardous waste) tons 13.2 46
Solid wastes emission by segment - Medical devices and medical diagnosis - Domestic waste tons 161.1 46
Solid wastes emission by segment - Medical devices and medical diagnosis - Industrial solid waste (non-hazardous waste) tons 74.9 46
Solid wastes emission by segment - Pharmaceutical manufacturing and research and development - Domestic waste tons 2191.8 46
Solid wastes emission by segment - Pharmaceutical manufacturing and research and development - Industrial solid waste (non-hazardous waste) tons 77610.9 46
Solid wastes emission by segment - Total - Domestic waste tons 5414.4 46
Solid wastes emission by segment - Total - Industrial solid waste (non-hazardous waste) tons 77699 46
Total Solid Waste tons/year 80848 88967 85796.6 43
Total amount of solid waste generated by the Group's domestic enterprises tons 85796.6 46
Total solid waste tons/year 80848 88967 85796.6 87
Total solid waste intensity (Unit: kg/RMB10000 of output value) kg/RMB10000 of output value 48.01 34.36 43

Description of emissions target(s) set and steps taken to achieve them.

Indicator Unit 2018 Report Pages
Emission of greenhouse gases compared with 2017 % -4.4 50
Total carbon emission reduction by the Group tons 5995 51

Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.

Indicator Unit 2018 Report Pages
Hazardous waste incinerated tons 2538.6 46
Industrial solid waste delivered to external qualified units for compliant treatment and recycling tons 72690 46
Operation Expenditure of environmental facilities - Healthcare services RMB/000 451.1 47
Operation Expenditure of environmental facilities - Medical devices and medical diagnosis RMB/000 35.9 47
Operation Expenditure of environmental facilities - Pharmaceutical manufacturing and research and development RMB/000 9335.4 47
Operation Expenditure of environmental facilities - Total RMB/000 9840.4 47

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 Report Pages
Diesel consumption in Medical devices and medical diagnosis ton 382 48
Diesel consumption in Pharmaceutical manufacturing and research and development ton 2812 48
Electricity consumption kWh/year 478715186 513272112 655108860 47
Electricity consumption in Healthcare services kWh/year 31687279 48
Electricity consumption in Medical devices and medical diagnosis kWh/year 15111281 48
Electricity consumption in Pharmaceutical manufacturing and research and development kWh/year 60808950 48
Energy consumption other than electricity GJ/year 3860500 4648903 5394870 47, 87
Fuel oil consumption in Healthcare services ton 20 48
Fuel oil consumption in Pharmaceutical manufacturing and research and development ton 4305 48
Gasoline consumption in Healthcare services Liter 81410 48
Gasoline consumption in Medical devices and medical diagnosis Liter 171359 48
Gasoline consumption in Pharmaceutical manufacturing and research and development Liter 222548 48
Liquefied gas consumption in Healthcare services kg 14228 48
Liquefied gas consumption in Pharmaceutical manufacturing and research and development kg 38990 48
Natural gas consumption in Healthcare services m³ 813724 48
Natural gas consumption in Medical devices and medical diagnosis m³ 216388 48
Natural gas consumption in Pharmaceutical manufacturing and research and development m³ 15090438 48
Raw coal consumption in Pharmaceutical manufacturing and research and development ton 70115 48
Steam consumption in Pharmaceutical manufacturing and research and development ton 246596 48
Total diesel consumption ton 3256 48
Total electricity consumption kWh/year 478175186 513272112 65510860 48, 87
Total energy consumption GJ/year 5581931 6496683 7753262 47, 87
Total energy consumption of the Group 73152626 48
Total energy intensity GJ/RMB10000 of output value, GJ/RMB1000000 of output value 4.43 3.51 3.11 47, 87
Total fuel oil consumption ton 4325 48
Total gasoline consumption Liter 475317 48
Total liquefied gas consumption kg 53218 48
Total natural gas consumption m³ 16120550 48
Total raw coal consumption ton 70115 48
Total steam consumption ton 246596 48

Water consumption in total and intensity (e.g. per unit of production volume, per facility).

Indicator Unit 2016 2017 2018 Report Pages
Total water consumption m³, m³/year 8769376 9515697 9959415 47, 48, 87
Total water consumption in Healthcare services m³/year 1136839 48
Total water consumption in Medical devices and medical diagnosis m³/year 186442 48
Total water consumption in Pharmaceutical manufacturing and research and development m³/year 8636134 48
Total water saving of the Group m³ 178704 48
Water consumption intensity m³/RMB10000 of output value, m³/RMB1000000 of output value 5.99 ↓22.4% 3.99 47, 48
Water intensity m³/RMB10000 of output value 5.99 5.14 3.99 87
Water saving volume for Dongting Pharma 10000 m³ 0.5 48
Water saving volume for Erye Pharma 10000 m³ 0.8 48
Water saving volume for Gland Pharma 10000 m³ 3.1 48
Water saving volume for Guilin Pharma 10000 m³ 2.9 48
Water saving volume for Laishi Transfusion 10000 m³ 1.5 48
Water saving volume for Wanbang Biopharma 10000 m³ 1.4 48
Water saving volume for Yao Pharma 10000 m³ 7.1 48

Description of energy use efficiency target(s) set and steps taken to achieve them.

Indicator Unit 2018 Report Pages
Capital Expenditure of environmental facilities - Healthcare services RMB/000 137.1 47
Capital Expenditure of environmental facilities - Medical devices and medical diagnosis RMB/000 26.8 47
Capital Expenditure of environmental facilities - Pharmaceutical manufacturing and research and development RMB/000 5947.8 47
Capital Expenditure of environmental facilities - Total RMB/000 6111.7 47
Capital Expenditure on Safety - Healthcare services RMB'000 332.1 58
Capital Expenditure on Safety - Medical devices and medical diagnosis RMB'000 133.4 58
Capital Expenditure on Safety - Pharmaceutical manufacturing and research and development RMB'000 1381.2 58
Capital Expenditure on Safety - Total RMB'000 1846.7 58
Electricity saved by Chemo Biopharm kWh 92000 51
Electricity saved by Dongting Pharma kWh 100000 51
Electricity saved by Erye Pharma kWh 50000 51
Electricity saved by Gland Pharma kWh 22000 51
Electricity saved by Guangji Hospital kWh 499000 51
Electricity saved by Guilin Pharma kWh 3482000 51
Electricity saved by Hongqi Pharma kWh 1310000 51
Electricity saved by Huaiyin Medical kWh 50000 51
Electricity saved by Jiangsu Changxing kWh 500000 51
Electricity saved by Wanbang Folon kWh 59000 51
Electricity saved by Yaneng Bio kWh 326000 51
Electricity saved by Yao Pharma kWh 650000 51
Electricity saved by Zhaohui Pharma kWh 79000 51
Natural gas saved by Carelife Pharma m³ 7000 51
Natural gas saved by Dongting Pharma m³ 10000 51
Natural gas saved by Guilin Pharma m³ 384000 51
Natural gas saved by Jimin Cancer Hospital m³ 25000 51
Natural gas saved by Wanbang Folon m³ 12000 51
Natural gas saved by Yao Pharma m³ 342000 51
Steam saved by Shanghai Transfusion tons 15000 51
Total electricity saved by the Group kWh 7230000 51
Total natural gas saved by the Group m³ 780000 51
Total steam saved by the Group tons 15000 51

Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.

Indicator Unit 2018 Report Pages
Total amount of packaging materials - All segments tons/year 18371 49
Total amount of packaging materials - Healthcare services tons/year 24 49
Total amount of packaging materials - Medical technologies tons/year 1062 49
Total amount of packaging materials - Pharmaceutical manufacturing and research and development tons/year 17285 49
Total packaging materials tons/year 18371 47
Type of packaging materials consumed - Glass ton 5647 49
Type of packaging materials consumed - Metal ton 822 49
Type of packaging materials consumed - Others ton 125 49
Type of packaging materials consumed - Paper ton 8341 49
Type of packaging materials consumed - Plastic ton 2432 49
Type of packaging materials consumed - Rubber ton 824 49
Type of packaging materials consumed - Wood ton 180 49
Use of packaging materials - Paper tons 91 49

Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.

Indicator Unit 2016 2017 2018 Report Pages
Clean production certifications N/A N/A 13 59
ISO14001 certifications 10 12 15 59
Investment in environmental protection RMB'000, RMB/000 3346 7348 15952 47, 87
Number of subsidiaries completed assessment and certification of corporate clean production subsidiaries 13 61
Number of subsidiaries conducting soil and groundwater monitoring subsidiaries 10 53
Number of subsidiaries received third party certifications of ISO14001 and/or OHSAS18001 subsidiaries 15 61

Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.

Indicator Unit 2016 2017 2018 Report Pages
Employee welfare fees (Fosun Pharma Group) RMB'000 7614 8739 12528 74
Employment rate of ethnic minority employees % 2.48 1.6 2.03 86
Employment rate of people with disabilities % 0.36 0.26 0.23 86
Global Employee Distribution - Central China (Hubei, Hunan, Henan, Jiangxi) People 3442 3543 3853 68
Global Employee Distribution - Eastern China (Shandong, Jiangsu, Anhui, Zhejiang, Fujian, Shanghai) People 9013 10096 11054 68
Global Employee Distribution - Hong Kong, Macao and Taiwan People 14 14 68
Global Employee Distribution - Northeast China (Liaoning, Jilin, Heilongjiang) People 1387 1500 1493 68
Global Employee Distribution - Northern China (Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia) People 191 241 280 68
Global Employee Distribution - Overseas People 343 4448 4844 68
Global Employee Distribution - Southern China (Guangdong, Guangxi, Hainan) People 3276 4604 4742 68
Global Employee Distribution - Southwest China (Sichuan, Yunnan, Guizhou, Tibet, Chongqing) People 2001 1951 1869 68
Housing provident fund (Fosun Pharma Group) RMB'000 7673 9137 11552 74
Labor contract conclusion rate 100% 100% 100% 86
Number of R&D staff (excluding QA and QC employees) 995 1353 1797 86
Number of employees aged 16–20 People 176 106 140 67
Number of employees aged 20–30 People 6513 8951 9768 67
Number of employees aged 30–40 People 6135 8887 9964 67
Number of employees aged 40–50 People 4747 5940 5886 67
Number of employees aged 50–55 People 1214 1546 1486 67
Number of employees aged 55–60 People 557 683 711 67
Number of employees aged 60–65 People 181 284 290 67
Number of employees with bachelor's degree People 5395 8133 9137 67
Number of employees with college degree People 4977 6541 7183 67
Number of employees with doctorate degree People 134 256 328 67
Number of employees with master's degree People 1021 2453 2922 67
Number of employees with technical school graduate or below People 7996 8954 8675 67
Number of ethnic minority employees 487 461 574 86
Overseas Employee Distribution - Africa People 664 68
Overseas Employee Distribution - Europe People 220 68
Overseas Employee Distribution - India People 3581 68
Overseas Employee Distribution - Israel People 433 68
Overseas Employee Distribution - United States People 16 68
Social insurance (Fosun Pharma Group) RMB'000 26615 31338 37185 74
Total labor costs (Fosun Pharma Group) RMB'000 225356 286396 390942 74
Total number of employees 19523 28884 25233 54, 86
Total number of employees - Healthcare services 5544 55
Total number of employees - Medical devices and medical diagnosis 2374 55
Total number of employees - Pharmaceutical manufacturing and research and development 17315 55
Total number of employees of Fosun Pharma Group People 19523 26397 28245 67
Total number of employees with master and doctor degrees 1155 2735 3250 86
Total number of female employees 9949 12764 13273 86
Total number of female employees of Fosun Pharma Group People 9949 12434 13273 67
Total number of male employees 9574 16084 14972 86
Total number of male employees of Fosun Pharma Group People 9574 13963 14972 67
Total working hours - Healthcare services hours 11082121 55
Total working hours - Medical devices and medical diagnosis hours 5184698 55
Total working hours - Pharmaceutical manufacturing and research and development hours 36777867 55
Union coverage rate 100% 100% 100% 86
Wages, bonus, subsidy and allowance (Fosun Pharma Group) RMB'000 180612 234775 324599 74

Employee turnover rate by gender, age group and geographical region.

Indicator Unit 2016 2017 2018 Report Pages
Employee Loss Rate 14.86% 16.93% 17.69% 68
Employee Outflow Rate 17.89% 20.54% 21.22% 68
Ration of female employee returning to work and job positions retained till after the completion of the maternity leave 100% 100% 100% 86

Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.

Indicator Unit 2016 2017 2018 Report Pages
LTI rate - Healthcare services 0.357 55
LTI rate - Pharmaceutical manufacturing and research and development 0.218 55
Loss time injury rate per million man-hour 0.58 0.415 0.226 87
Major injury rate per million man-hour 0.22 0.03 0.038 54
Minor injury accident rate 0.188 55
Minor injury rate per million man-hour 0.36 0.385 0.188 54
Number of Lost Time Injury (LTI) cases - Healthcare services case 4 55
Number of Lost Time Injury (LTI) cases - Pharmaceutical manufacturing and research and development case 8 55
Number of Recordable Incidents (RI) - Healthcare services 6 55
Number of Recordable Incidents (RI) - Pharmaceutical manufacturing and research and development 17 55
Number of major injury cases - Healthcare services 0.089 55
Number of major injury cases - Pharmaceutical manufacturing and research and development 0.027 55
Number of minor injury cases - Healthcare services 0.268 55
Number of minor injury cases - Pharmaceutical manufacturing and research and development 0.191 55
Occupational hazard exposure rate % 14.89% 12.42% 12.34% 54, 87
RI rate - Healthcare services 0.536 55
RI rate - Pharmaceutical manufacturing and research and development 0.462 55
Rate of injury incident case per 1000000 working hours 0.038 55
Recordable accident rate 0.233 55
Recordable incident rate per million man-hour 1.04 0.915 0.433 54
Recordable injury rate per million man-hour 1.05 0.915 0.433 87

Lost days due to work injury.

Indicator Unit 2016 2017 2018 Report Pages
Lost time - Healthcare services hours 69 55
Lost time - Pharmaceutical manufacturing and research and development hours 233 55
Lost time injury rate (excluding offsite) 0.226 55
Lost time injury rate change compared to 2017 % -45.6 54
Lost time injury rate per million man-hour 0.58 0.415 0.223 54

Description of occupational health and safety measures adopted, and how they are implemented and monitored.

Indicator Unit 2016 2017 2018 Report Pages
Completion rate of occupational health examination in Healthcare services percent 100% 57
Completion rate of occupational health examination in Medical devices and medical diagnosis percent 100% 57
Completion rate of occupational health examination in Pharmaceutical manufacturing and research and development percent 100% 57
H&S investment RMB'000 3155 3919 3843 54
Highest score among those who scored 3 and above in EHS responsibility system at Yaneng Bio 3.4 60
Investment in fixed assets for occupational health and safety RMB'000 1846.7 58
Investment in health and safety RMB'000 3155 3919 3843 87
Number of EHS essays collected during EHS management month activity at Guilin Pharma essays 205 60
Number of EHS footprint photos collected during EHS management month activity at Guilin Pharma photos 1000 60
Number of EHS members involved in EHS management month activity at Guilin Pharma members 35 60
Number of employees arranged to take physical examination employees 10000 75
Number of employees exposed to occupational hazards in Healthcare services employees 347 57
Number of employees exposed to occupational hazards in Medical devices and medical diagnosis employees 95 57
Number of employees exposed to occupational hazards in Pharmaceutical manufacturing and research and development employees 2671 57
Number of employees required for occupational health examination in Healthcare services employees 346 57
Number of employees required for occupational health examination in Medical devices and medical diagnosis employees 95 57
Number of employees required for occupational health examination in Pharmaceutical manufacturing and research and development employees 2498 57
Number of subsidiaries passed third party assessment on safety and quality standardization of the PRC subsidiaries 24 61
OHSAS18001 certifications 9 11 15 59
Occupational health and safety operation costs RMB'000 1995.9 58
Operation Expenditure on Safety - Healthcare services RMB'000 85 58
Operation Expenditure on Safety - Medical devices and medical diagnosis RMB'000 87.5 58
Operation Expenditure on Safety - Pharmaceutical manufacturing and research and development RMB'000 1823.4 58
Operation Expenditure on Safety - Total RMB'000 1995.9 58
Other expenses (Fosun Pharma Group) RMB'000 841 247 2072 74
Percentage of employees exposed to occupational hazards in Healthcare services percent 6.26% 57
Percentage of employees exposed to occupational hazards in Medical devices and medical diagnosis percent 4.00% 57
Percentage of employees exposed to occupational hazards in Pharmaceutical manufacturing and research and development percent 15.43% 57
Safety Standardization Certification - Aleph Class III Safety Standardization 61
Safety Standardization Certification - Aohong Pharma clean production 61
Safety Standardization Certification - Carelife Pharma Class II Safety Standardization 61
Safety Standardization Certification - Chemo Biopharm ISO14001, OHSAS18001, Class I Safety Standardization, clean production 61
Safety Standardization Certification - Dongting Pharma ISO14001*, OHSAS18001*, Class I Safety Standardization, clean production 61
Safety Standardization Certification - Eyre Pharma ISO14001, OHSAS18001, Class I Safety Standardization, clean production 61
Safety Standardization Certification - Fosun Biolog Class II Safety Standardization 61
Safety Standardization Certification - Gland Pharma ISO14001*, OHSAS18001 61
Safety Standardization Certification - Guilin Pharma ISO14001, OHSAS18001, Class I Safety Standardization, clean production 61
Safety Standardization Certification - Hongqi Pharma ISO14001, OHSAS18001, Class II Safety Standardization 61
Safety Standardization Certification - Huanghai Pharma ISO14001*, OHSAS18001*, Class II Safety Standardization 61
Safety Standardization Certification - Huayin Medical Class III Safety Standardization, clean production 61
Safety Standardization Certification - Jiangsu Changxing Class II Safety Standardization* 61
Safety Standardization Certification - Jimin Cancer Hospital ISO14001, OHSAS18001*, Class I Safety Standardization 61
Safety Standardization Certification - Laishi Transfusion Class III Safety Standardization*, clean production 61
Safety Standardization Certification - Long March Medical Class II Safety Standardization 61
Safety Standardization Certification - Research Institute Pharma ISO14001*, OHSAS18001*, Class II Safety Standardization 61
Safety Standardization Certification - Shanghai Transfusion Class III Safety Standardization, clean production 61
Safety Standardization Certification - Shine Star ISO14001*, OHSAS18001*, Class II Safety Standardization 61
Safety Standardization Certification - Wanbang Biopharma ISO14001, OHSAS18001, Class III Safety Standardization, clean production 61
Safety Standardization Certification - Wanbang Folon ISO14001, OHSAS18001, Class III Safety Standardization, clean production 61
Safety Standardization Certification - Wanbang Jinqiao ISO14001, OHSAS18001, Class I Safety Standardization, clean production 61
Safety Standardization Certification - Wanbang Tiansheng Class II Safety Standardization 61
Safety Standardization Certification - Wenzhou Geriatrics Hospital Class II Safety Standardization 61
Safety Standardization Certification - Yao Pharma ISO14001, OHSAS18001, Class II Safety Standardization, clean production 61
Safety Standardization Certification - Zhouhai Pharma ISO14001, OHSAS18001, Class I Safety Standardization, clean production 61
Safety Standardization certifications 21 22 24 59
Total EHS training hours hours 93431 185067 237572 87
Total EHS training time hour 93431 185067 237572 59
Total completion rate of occupational health examination percent 100% 57
Total investment in occupational health and safety RMB'000 3842.6 58
Total number of employees exposed to occupational hazards employees 3113 57
Total number of employees required for occupational health examination employees 2939 57
Total percentage of employees exposed to occupational hazards percent 12.34% 57

The percentage of employees trained by gender and employee category (e.g. senior management, middle management).

Indicator Unit 2016 2017 2018 Report Pages
Number of customer and doctor training and communication meetings held 600 37
Number of employees borrowing books from Xinglong Library employees 400 75
Number of employees participating in precision stretching activities employees 100 75
Number of minister level seminars on field drug regulation in developing countries undertaken by Fosun Pharma Group seminars 4 79
Number of provincial academic conferences attended 11 37
Of which: Training for Fresh Graduates (including former employees) - Number of persons Person 543 738 845 70
R&D expense RMB'0000 71400.75 102600.54 147961.23 25
R&D spending (including expenditures capitalized) RMB'0000 110600 152900.29 250683.56 25
Training for Senior Management - Number of persons Person 249 374 376 70
Training for Senior Management - Total training person time Person time 6348 7831 15412 70
Training for employees (including fresh graduates) other than senior management - Number of persons Person 21255 22275 25144 70
Training for employees (including fresh graduates) other than senior management - Total training person time Person time 710701 963408 839581 70

The average training hours completed per employee by gender and employee category.

Indicator Unit 2016 2017 2018 Report Pages
Annual quality training hours per capita - Aohong Pharma hours 24.1 33
Annual quality training hours per capita - Erye Pharma hours 32.6 33
Annual quality training hours per capita - Guilin Pharma hours 26.2 33
Annual quality training hours per capita - Hongqi Pharma hours 61.3 33
Annual quality training hours per capita - Wanbang Biopharma hours 40.2 33
Annual quality training hours per capita - Yao Pharma hours 42.8 33
Annual quality training hours per capita of pharmaceutical manufacturing member companies hours 44 33
Average Training Hours Per Person - All employees hours/person 33 43 34 70
Average Training Hours Per Person - Of which, female employees hours/person 37 47 32 70
Average Training Hours Per Person - Of which, male employees hours/person 31 40 37 70
EHS training hours per employee hours 5.75 7.86 9.42 87
EHS training time per person hour 5.75 7.86 9.42 59
EHS training times per employee time 2.1 1.8 2.5 87
External training hours per person - Diagnostic reagents subsidiaries hours 16.7 33
External training hours per person - Medical device consumables subsidiaries hours 27.4 33
External training total hours - Diagnostic reagents subsidiaries hours 1373 33
External training total hours - Medical device consumables subsidiaries hours 1975 33
Internal training hours per person - Diagnostic reagents subsidiaries hours 16.1 33
Internal training hours per person - Medical device consumables subsidiaries hours 11.8 33
Internal training total hours - Diagnostic reagents subsidiaries hours 8894 33
Internal training total hours - Medical device consumables subsidiaries hours 6481 33
Number of EHS training times per person 2.1 1.8 2.5 59
Of which: Training for Fresh Graduates (including former employees) - Total training person time Person time 65639 53229 43248 70
Research and development expenses (including capitalized expenses) RMB100000000 11.06 15.29 25.07 86
Total Training Expenses Amount (RMB'000) 819 686 993 70
Total training hours (man-hour) 717049 971239 854993 86

Number of suppliers by geographical region.

Indicator Unit 2018 Report Pages
Number of suppliers in Anhui (Fosun Pharma subsidiaries) 91 36
Number of suppliers in Beijing (Fosun Pharma subsidiaries) 94 36
Number of suppliers in Chongqing (Fosun Pharma subsidiaries) 109 36
Number of suppliers in Fujian (Fosun Pharma subsidiaries) 15 36
Number of suppliers in Gansu (Fosun Pharma subsidiaries) 6 36
Number of suppliers in Guangdong (Fosun Pharma subsidiaries) 203 36
Number of suppliers in Guangxi (Fosun Pharma subsidiaries) 70 36
Number of suppliers in Hainan (Fosun Pharma subsidiaries) 12 36
Number of suppliers in Hebei (Fosun Pharma subsidiaries) 110 36
Number of suppliers in Heilongjiang (Fosun Pharma subsidiaries) 7 36
Number of suppliers in Henan (Fosun Pharma subsidiaries) 39 36
Number of suppliers in Hong Kong, Macau, and Taiwan (Fosun Pharma subsidiaries) 7 36
Number of suppliers in Hubei (Fosun Pharma subsidiaries) 72 36
Number of suppliers in Hunan (Fosun Pharma subsidiaries) 82 36
Number of suppliers in Inner Mongolia (Fosun Pharma subsidiaries) 11 36
Number of suppliers in Jiangsu (Fosun Pharma subsidiaries) 523 36
Number of suppliers in Jiangxi (Fosun Pharma subsidiaries) 33 36
Number of suppliers in Jilin (Fosun Pharma subsidiaries) 17 36
Number of suppliers in Liaoning (Fosun Pharma subsidiaries) 85 36
Number of suppliers in Ningxia (Fosun Pharma subsidiaries) 3 36
Number of suppliers in Overseas countries (Fosun Pharma subsidiaries) 205 36
Number of suppliers in Qinghai (Fosun Pharma subsidiaries) 7 36
Number of suppliers in Shaanxi (Fosun Pharma subsidiaries) 20 36
Number of suppliers in Shandong (Fosun Pharma subsidiaries) 200 36
Number of suppliers in Shanghai (Fosun Pharma subsidiaries) 445 36
Number of suppliers in Shanxi (Fosun Pharma subsidiaries) 21 36
Number of suppliers in Sichuan (Fosun Pharma subsidiaries) 87 36
Number of suppliers in Tianjin (Fosun Pharma subsidiaries) 38 36
Number of suppliers in Tibet (Fosun Pharma subsidiaries) 2 36
Number of suppliers in Xinjiang (Fosun Pharma subsidiaries) 10 36
Number of suppliers in Yunnan (Fosun Pharma subsidiaries) 8 36
Number of suppliers in Zhejiang (Fosun Pharma subsidiaries) 250 36
Number of suppliers involved in business for the year (Aohong Pharma) 60 36
Number of suppliers involved in business for the year (Erye Pharma) 166 36
Number of suppliers involved in business for the year (Guilin Pharma) 241 36
Number of suppliers involved in business for the year (Hongqi Pharma) 94 36
Number of suppliers involved in business for the year (Wanbang Bipharma) 592 36
Number of suppliers involved in business for the year (Yao Pharma) 349 36

Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.

Indicator Unit 2018 Report Pages
Number of suppliers involved in green supply chain extension audit 150 37
Number of suppliers under annual review (Aohong Pharma) 60 36
Number of suppliers under annual review (Erye Pharma) 106 36
Number of suppliers under annual review (Guilin Pharma) 241 36
Number of suppliers under annual review (Hongqi Pharma) 94 36
Number of suppliers under annual review (Wanbang Bipharma) 553 36
Number of suppliers under annual review (Yao Pharma) 262 36
Number of suppliers under review/Number of suppliers involved in business for the year (Aohong Pharma) 100.0% 36
Number of suppliers under review/Number of suppliers involved in business for the year (Erye Pharma) 63.9% 36
Number of suppliers under review/Number of suppliers involved in business for the year (Guilin Pharma) 100.0% 36
Number of suppliers under review/Number of suppliers involved in business for the year (Hongqi Pharma) 100.0% 36
Number of suppliers under review/Number of suppliers involved in business for the year (Wanbang Bipharma) 93.4% 36
Number of suppliers under review/Number of suppliers involved in business for the year (Yao Pharma) 75.1% 36
On-site audit rate of suppliers in green supply chain extension % 27 37

Number of products and service related complaints received and how they are dealt with.

Indicator Unit 2016 2017 2018 Report Pages
Completeness of disclosed indicators in biomedical manufacturing industry percent 71.92 99
Customer complaint response rate % 100% 35
Customer satisfaction rate for diagnostic reagent enterprises (Long March Medical and Yaneng Bioscience) % 95% 35
Number of customer complaints received by Group (medical device members) complaints 281 35
Number of customer complaints received by pharmaceutical subsidiaries complaints 25 35
Number of customer satisfaction surveys conducted by diagnostic reagent enterprises (Long March Medical and Yaneng Bioscience) surveys 287 35
Revenue from healthcare services segment RMB'0000 167756 208847.03 256296.75 21
Revenue from medical devices and medical diagnosis manufacturing segment RMB'0000 266391 321405.08 363886.91 21
Revenue from pharmaceutical manufacturing and research and development business segment RMB'0000 1025954 1319547.17 1868134.51 21

Description of practices relating to observing and protecting intellectual property rights.

Indicator Unit 2016 2017 2018 Report Pages
Number of antimalarial drugs pre-certified by the World Health Organization held by Fosun Pharma Group drugs 14 79
Number of antimalarial patients served by Fosun Pharma's intellectual property million patients 20 79
Number of patent application 103 84 99 86
Number of patent applications submitted (pharmaceutical manufacturing and R&D businesses) 99 25
Number of patent granted 30 25 35 86
Number of patents obtained (all for invention) 35 25
Number of pipeline drugs, biosimilars and consistency evaluation projects 215 25

Description of quality assurance process and recall procedures.

Indicator Unit 2018 Report Pages
Number of drug recall drills conducted by domestic pharmaceutical subsidiaries drills 11 35

Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.

Indicator Unit 2016 2017 2018 Report Pages
Under investigation items (items) 173 171 215 86

Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).

Indicator Unit 2018 Report Pages
Basic support to disabled people by Wanbang Biopharma RMB 849000 80
Number of activities held attracting nearly 1000 people activities 27 75
Number of club activities carried out throughout the year activities 359 75
Number of club members members 1180 75
Number of countries involved in Fosun Pharma Group's malaria aid activities countries 50 79
Number of employee clubs established clubs 10 75
Number of health lectures, disease prevention and nursing knowledge sessions held by Yao Pharma sessions 30 83
Number of online education sessions held 21 37
Number of seminars on malaria prevention and treatment in developing countries undertaken by Fosun Pharma Group seminars 10 79
Number of seminars on quality management in developing countries undertaken by Fosun Pharma Group seminars 6 79
Scholarship investment for comprehensive development of students with financial difficulties RMB 1000000 80
Scholarship investment for education and development of poor students by Wanbang Biopharma RMB 12000000 80
Support to impoverished disabled people by Wanbang Biopharma people 120 80
Support to poor and disabled children by Wanbang Biopharma RMB 646000 80
Tax payment billion RMB 2.69 7

Resources contributed (e.g. money or time) to the focus area.

Indicator Unit 2016 2017 2018 Report Pages
Amount of employee mutual fund RMB 8500000 75
Investment in Double Thousand Actions for tuberculosis patients RMB 12000000 80
Investment in targeted poverty alleviation by Fosun Pharma and its subsidiaries RMB 118200000 80
Investment in targeted poverty alleviation project by Jimin Cancer Hospital RMB 2010000 80
Number of books borrowed from Xinglong Library by employees books 735 75
Number of families benefiting from 'Yao Pharma benefits all' campaign 5000 37
Number of foreign aid projects completed by Fosun Pharma Group projects 148 79
Number of people benefited from Jade Ribbon Campaign by Yao Pharma people 100000 83
Number of public service activities participated by Fosun Pharma in 2018 activities 4 83
Number of volunteer services organized by Chancheng Hospital services 11 83
Number of volunteers in Chancheng Hospital volunteer services volunteers 1067 83
Number of volunteers involved in Wenzhou Geriatrics Hospital volunteer activities volunteers 1600 83
Revenue RMB'0000, billion RMB 1462882.04 1853355.54 24.918 7, 21
Social Contribution per Share 2.99 3.84 3.97 86
Social contribution value per share of Fosun Pharma Group RMB 3.97 79
Total community charity donations by Fosun Pharma Group million RMB 7.5 79
Value of D-ARTEP donation to Zambian Ministry of Health by Fosun Pharma USD 240000 79

The types of emissions and respective emissions data.

Standard Indicator Unit 2016 2017 2018
Airborne Particulate Matter (PM) Emissions tons/year 19 41 44
NOₓ Emissions tons/year 466 239 251
SOₓ Emissions tons/year 485 245 279

Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018
Direct GHG Emissions (Scope 1) ton 288447 338285 397106
Indirect Energy Emissions (Scope 2) ton 457732 484501 389265
Total GHG Emissions ton 746179 822786 786371

Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2017 2018
Hazardous Waste (Other Recovery) tons 115.9
Hazardous Waste Landfilling tons 28.7
Total Hazardous Waste tons 2683.2
Total Hazardous Waste Intensity (By Revenue) kg/RMB10000 of output value 1.29 1.07

Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018
Non-Hazardous Waste (Domestic Waste) tons 5414.4
Non-Hazardous Waste Disposed tons 80848 88967 85796.6
Total Non-Hazardous Waste Intensity (By Revenue) kg/RMB10000 of output value 48.01 34.36

Description of emissions target(s) set and steps taken to achieve them.

Standard Indicator Unit 2018
GHG Emissions Reduction Compared to Last Year tons 5995
GHG Emissions Reduction Percentage Compared to Last Year % -4.4

Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.

Standard Indicator Unit 2018
Hazardous Waste Intensity Reduction Percentage Compared to Last Year % None

Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018
Diesel Fuel Consumption ton 3256
Energy Consumption Intensity (By Revenue) GJ/RMB1000000 of output value 4.43 3.51 3.11
Fossil Fuel Consumption ton 70115
Gasoline Consumption Liter 475317
Heating Oil Consumption ton 4325
LPG Consumption kg 53218
Natural Gas Consumption m³ 16120550
Purchased Steam ton 246596
Total Direct Energy Consumption GJ/year 3860500 4648903 5394870
Total Energy Consumption GJ/year 5581931 6496683 7753262
Total Indirect Energy Consumption kWh/year 478715186 513272112 655108860

Water consumption in total and intensity (e.g. per unit of production volume, per facility).

Standard Indicator Unit 2016 2017 2018
Water Consumption m³/year 8769736 9515697 9959415
Water Consumption Intensity (By Revenue) m³/RMB1000000 of output value 5.99 5.14 3.99

Description of energy use efficiency target(s) set and steps taken to achieve them.

Standard Indicator Unit 2018
Electricity Usage Reduction Compared to Last Year kWh 7230000
Investment in Energy-saving and Emission-reduction Technology Transformation RMB/000 6111.7
Steam Usage Reduction Compared to Last Year tons 15000

Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.

Standard Indicator Unit 2018
Packaging Material Consumption (Glass) ton 5647
Packaging Material Consumption (Metal) ton 822
Packaging Material Consumption (Paper) ton 8341
Packaging Material Consumption (Plastic) ton 2432
Packaging Material Consumption (Rubber) ton 824
Packaging Materials Consumed tons/year 18371
Usage of Packaging Materials (Wood) ton 180

Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.

Standard Indicator Unit 2016 2017 2018
Total Investment in Ecological Restoration RMB'000 3346 7348 15952

Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.

Standard Indicator Unit 2016 2017 2018
Number of Bachelor's Degree Employees People 5395 8133 9137
Number of Below Junior College Employees People 7996 8954 8675
Number of Doctoral Degree Employees People 134 256 328
Number of Employees Aged 30-50 People 10882 14827 15850
Number of Employees Aged Above 50 People 1952 2513 2487
Number of Employees Aged Below 30 People 6689 9057 9908
Number of Employees in Central China People 3442 3543 3853
Number of Employees in East China People 9013 10096 11054
Number of Employees in Hong Kong People 14 14
Number of Employees in North China People 191 241 280
Number of Employees in Northeast China People 1387 1500 1493
Number of Employees in Overseas People 343 4448 4844
Number of Employees in South China People 3276 4604 4742
Number of Employees in Southwest China People 2001 1951 1869
Number of Female Employees People 9949 12434 13273
Number of Male Employees People 9574 13963 14972
Number of Master's Degree Employees People 1021 2453 2922
Number of Total Employees People 19523 26397 28245

Employee turnover rate by gender, age group and geographical region.

Standard Indicator Unit 2016 2017 2018
Percentage of Employees still Employed 12 Months after Return to Work (Female) % 100 100 100
Turnover Rate of Total Employees % 14.86 16.93 17.69

Lost days due to work injury.

Standard Indicator Unit 2016 2017 2018
Lost Days Due to Work-related Injuries hours 302
Lost Time Injury Frequency Rate (LTIFR/LTIR) per million man-hour 0.58 0.415 0.223

Description of occupational health and safety measures adopted, and how they are implemented and monitored.

Standard Indicator Unit 2016 2017 2018
Health Check Coverage for Employees percent 100
Investment in Work Safety RMB'000 3155 3919 3842.6
Total Hours of Safety Training for Employees hours 93431 185067 237572

The percentage of employees trained by gender and employee category (e.g. senior management, middle management).

Standard Indicator Unit 2016 2017 2018
Percentage of Trained General Employees % 98.86 98.35 98.54
Percentage of Trained Senior Management % 1.14 1.65 1.46

The average training hours completed per employee by gender and employee category.

Standard Indicator Unit 2016 2017 2018
Average Training Hours (Female) hours/person 37 47 32
Average Training Hours (Male) hours/person 31 40 37
Average Training Hours per Employee hours/person 33 43 34
Total Training Hours hours 717049 971239 854993
Training Hours of ESG hours/person 5.75 7.86 9.42

Number of suppliers by geographical region.

Standard Indicator Unit 2018
Number of Suppliers in Hong Kong 7
Number of Suppliers in Mainland China 2835
Number of Suppliers in Overseas 205
Number of Total Suppliers 3252

Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.

Standard Indicator Unit 2018
Percentage of Critical Suppliers Covered by CSR Audit % 27

Number of products and service related complaints received and how they are dealt with.

Standard Indicator Unit 2018
Satisfaction Rate of Customer Complaint Handling % 95
Total Number of Customer Complaints complaints 306

Description of practices relating to observing and protecting intellectual property rights.

Standard Indicator Unit 2016 2017 2018
Number of Invention Patents 35
Number of Patents Applied 103 84 99
Number of Patents Granted 30 25 35

Description of quality assurance process and recall procedures.

Standard Indicator Unit
Passing Rate of Third-party Accreditation Performed under the Quality Management System %

Resources contributed (e.g. money or time) to the focus area.

Standard Indicator Unit 2018
Investment in Targeted Poverty Alleviation RMB 118200000
Number of Registered Volunteers volunteers 2667
Number of Volunteer Activities Sessions sessions 15
Number of Volunteers among Employees volunteers 100
Total Social Investment RMB 140950000